Department of Anesthesia and Critical Care, the Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Zhejiang, 325027, China.
School of Laboratory Medicine and Life Science, Wenzhou Medical University, Zhejiang, 325027, China.
Lab Invest. 2018 Jun;98(6):715-733. doi: 10.1038/s41374-018-0031-x. Epub 2018 Feb 21.
Inflammation always accompanies infection during sepsis. Mitochondrial dysfunction and the role of reactive oxygen species (ROS) produced by mitochondria have been proposed in the pathogenesis of sepsis. Maresins have protective and resolving effects in experimental models of infection. In the present study, we investigated the effects of maresin 1 (MaR1) on mitochondrial function in cecal ligation and puncture (CLP)-induced sepsis and sepsis patients to identify mechanisms underlying maresin 1-mediated stimulation of ROS in mitochondria. We found that treatment with MaR1 significantly inhibited production of cytokines, decreased bacterial load in the peritoneal lavage fluid, reduced the number of neutrophils, decreased lactic acid level and upregulated cyclic AMP (cAMP) concentration, with the outcome of decreased lung injury in CLP-induced sepsis in mice. The effects of MaR1 on downregulation nitric oxide (NOX) activity, improvement CAT and SOD activity to inhibit ROS production in mitochondria was dependent on lipoxin receptor (ALX) and cAMP. Survival rates were significantly increased after the treatment of mice with MaR1. In BMDM stimulated with LPS, MaR1 inhibited the ROS production, downregulated enzyme activity, reduced mtO2 production, increased mitochondrial membrane potential, improved adenosine triphosphate (ATP) content and mitochondrial DNA (mtDNA) copy number. Finally, the effects of MaR1 on ROS production in the blood of healthy volunteers stimulated with LPS or sepsis patients were associated with ALX and cAMP. Taken together, these data suggest that treatment with MaR1 could attenuate mitochondrial dysfunction during sepsis through regulating ROS production.
在脓毒症中,炎症总是伴随着感染。线粒体功能障碍和线粒体产生的活性氧物质(ROS)在脓毒症的发病机制中起作用。maresin 在感染的实验模型中具有保护和解决作用。在本研究中,我们研究了maresin 1(MaR1)对盲肠结扎和穿刺(CLP)诱导的脓毒症和脓毒症患者中线粒体功能的影响,以确定maresin 1 介导的线粒体 ROS 刺激的机制。我们发现,MaR1 治疗可显著抑制细胞因子的产生,减少腹腔灌洗液中的细菌负荷,减少中性粒细胞的数量,降低乳酸水平并上调环磷酸腺苷(cAMP)浓度,从而降低 CLP 诱导的脓毒症小鼠的肺损伤。MaR1 对下调一氧化氮合酶(NOX)活性、改善 CAT 和 SOD 活性以抑制线粒体中 ROS 产生的作用依赖于脂氧素受体(ALX)和 cAMP。MaR1 治疗后,小鼠的存活率显著提高。在 LPS 刺激的 BMDM 中,MaR1 抑制 ROS 产生,下调酶活性,减少 mtO2 产生,增加线粒体膜电位,改善三磷酸腺苷(ATP)含量和线粒体 DNA(mtDNA)拷贝数。最后,MaR1 对 LPS 刺激的健康志愿者或脓毒症患者血液中 ROS 产生的影响与 ALX 和 cAMP 有关。综上所述,这些数据表明,MaR1 治疗可通过调节 ROS 产生来减轻脓毒症中线粒体功能障碍。